N
Nigel Fleeman
Researcher at University of Liverpool
Publications - 49
Citations - 1283
Nigel Fleeman is an academic researcher from University of Liverpool. The author has contributed to research in topics: Cost effectiveness & Randomized controlled trial. The author has an hindex of 19, co-authored 44 publications receiving 1105 citations.
Papers
More filters
Journal ArticleDOI
Care delivery and self‐management strategies for children with epilepsy
TL;DR: There is currently limited evidence for the effectiveness of interventions to improve the health and quality of life in people with epilepsy, and it is not possible to advocate any single model of service provision.
Journal ArticleDOI
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.
Nigel Fleeman,Yenal Dundar,Rumona Dickson,Andrea L. Jorgensen,Sudeep Pushpakom,C McLeod,Munir Pirmohamed,Munir Pirmohamed,Tom Walley +8 more
TL;DR: Evidence of clinical validity and utility of CYP2D6 testing in patients being prescribed antipsychotics is lacking, and thus, routine pharmacogenetic testing prior to antipsychotic prescription cannot be supported at present.
Journal ArticleDOI
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Nigel Fleeman,C Martin Saborido,Katherine Payne,Angela Boland,Rumona Dickson,Yenal Dundar,A Fernández Santander,Sacha J Howell,William G. Newman,J Oyee,Tom Walley +10 more
TL;DR: Testing for cytochrome P450 2D6 (CYP2D6) polymorphisms in women with early hormone receptor positive breast cancer leads to improvement in outcomes, is useful for health decision-making and is a cost-effective use of health-care resources.
Journal ArticleDOI
Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis
Nigel Fleeman,Adrian Bagust,Angela Boland,Rumona Dickson,Yenal Dundar,M Moonan,James Oyee,Michaela Blundell,Hilary Davis,Anne C Armstrong,Nicola Thorp +10 more
TL;DR: The findings from the trials all suggest that LAP + AI or TRA + AI results in improved progression-free survival and/or time to progression when compared with AIs alone, but the trials do not show a statistically significant benefit in terms of overall survival.
Journal ArticleDOI
The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Amanda Nicholson,James Mahon,Angela Boland,Sophie Beale,Kerry Dwan,Nigel Fleeman,Juliet Hockenhull,Yenal Dundar +7 more
TL;DR: Evaluating the clinical effectiveness and cost-effectiveness of the PCA3 assay and the phi in the diagnosis of prostate cancer indicated that the use of these tests in the NHS would not be cost-effective.